| abstract |
The present invention relates to a combination formulation containing metformin for treating non-insulin dependent diabetes and an HMG-CoA reductase inhibitor for treating dyslipidemia. The present invention provides a combination formulation and a process for preparing the combination formulation, wherein the combination formulation contains metformin and an HMG-CoA reductase inhibitor, and has improved stability by effectively blocking chemical reactions and between the active ingredients while ensuring the constant release of the corresponding active ingredients. |